Skip to main content

Advertisement

SpringerLink
Log in

Asciminib as a third line option in chronic myeloid leukemia

  • Progress in Hematology
  • Chronic myeloid leukemia: the cutting-edge evidence and things we should know
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Unmet needs remain in the treatment of chronic phase chronic myeloid leukemia (CML) in later lines. Sequential use of tyrosine kinase inhibitors (TKIs) is associated with decreased overall survival and emergence of new mutations, particularly the T315I mutation. Among the new drugs developed to overcome resistance and intolerance, the STAMP inhibitor asciminib (which specifically targets the ABL myristoyl pocket) is the first example of a drug that works by allosteric inhibition. This review focuses on its mechanism of action, pharmacokinetic, efficacy, and toxicity, as well as how this drug will change the therapeutic approach for CML patients not eligible to receive other available drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7 

    Article  CAS  Google Scholar 

  2. Garcia-Gutierrez V, Hernandez-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9:603.

    Article  Google Scholar 

  3. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.

    Article  CAS  Google Scholar 

  4. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–40.

    Article  CAS  Google Scholar 

  5. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–54.

    Article  CAS  Google Scholar 

  6. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized before trial. J Clin Oncol. 2018;36:231–7.

    Article  CAS  Google Scholar 

  7. Hochhuas A, Saglio G, Hughes TP, et al. Impact of treatment with frontline nilotinib vs imatinib on sustained deep molecular response in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2015;126(23):2781.

    Article  Google Scholar 

  8. Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017;31(3):593–601.

    Article  CAS  Google Scholar 

  9. Breccia M, Chiodi F, Nardozza AP, et al. Real-world analysis of the therapeutic management and disease burden in chronic myeloid leukemia patients with later lines in Italy. J Clin Med. 2022;11(13):3597.

    Article  CAS  Google Scholar 

  10. Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44.

    Article  CAS  Google Scholar 

  11. Adrian FJ, Ding Q, Sim T, et al. Allosteric inhibitors of BCR-ABL dependent cell proliferation. Nat Chem Biol. 2006;2:95–102.

    Article  CAS  Google Scholar 

  12. Jahnke W, Grotzfeld RM, Pellè X, et al. Binding or bending: distinction of allosteric ABL kinase agonists from antagonists by an NMR-based conformational assay. J Am Chem Soc. 2010;132:7043–8.

    Article  CAS  Google Scholar 

  13. Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–7.

    Article  CAS  Google Scholar 

  14. Schoepfer J, Jahnke W, Berellini G, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61:8120–35.

    Article  CAS  Google Scholar 

  15. Manely PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98: 106458.

    Article  Google Scholar 

  16. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315–26.

    Article  CAS  Google Scholar 

  17. Cortes J, Lang F, Kim DW, et al. Combination therapy using asciminib plus imatinib (ima) in patients with chronic myeloid leukemia (CML): results from a phase 1 study. EHA. 2019;3:397.

    Google Scholar 

  18. Mauro MJ, Kim DW, Cortes J, et al. Combination of asciminib plus nilotinib (NIL) or dasatinib (DAS) in patients (pts) with chronic myeloid leukemia (CML): results from a phase 1 study. EHA 2019; S884.

  19. Cortes J, Hughes TP, Mauro MJ, et al. Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients with chronic myeloid leukemia (CML) harboring the T315I mutation: primary efficacy and safety results from a phase 1 trial. Blood. 2020;136(s1):47–50.

    Article  Google Scholar 

  20. Hughes TP, Cortes JE, Rea D, et al. Asciminib provides durable molecular responses in patients with chronic myeloid leukemia in chronic phase with the T315I mutation: updated efficacy and safety data from a phase I trial. EHA. 2022;6:599–600.

    Google Scholar 

  21. Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031–41.

    Article  Google Scholar 

  22. Mauro MJ, Minami Y, Rea D, et al. Efficacy and safety results from Ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after > prior tyrosine kinase inhibitors: update after 48 weeks. – ASH meeting December 2021 - Session: 632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Mechanisms of resistance and expanded therapies Hematology Disease Topics & Pathways.

  23. Rea D, Hochhaus A, Mauro MJ, Minami Y, Lomaia E, Voloshin S, et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after >2 prior tyrosine kinase inhibitors: wk 96 update. EHA 2022; abstract s155.

  24. ClinicalTrials.gov. Frontline asciminib combination in chronic phase CML (CMLXI). CML (CMLXI). https://clinicaltrials.gov/ct2/show/NCT03906292. Accessed 21 Jan 2021.

  25. ClinicalTrials.gov. ABL001 for the treatment of chronic myeloid leukemia in patients who are on therapy with tyrosine kinase inhibitor. https://clinicaltrials.gov/ct2/show/NCT04216563. Accessed 21 Jan 2021.

  26. ClinicalTrials.gov. Asciminib in monotherapy for chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML). https://clinicaltrials.gov/ct2/show/NCT04666259. Accessed 21 Jan 2021.

  27. ClinicalTrials.gov. Study of efficacy and safety of asciminib in combination with imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). https://clinicaltrials.gov/ct2/show/NCT03578367. Accessed 21 Jan 2021.

  28. ClinicalTrials.gov. Pharmacokinetics study of asciminib in subjects with impaired renal function compared to matched healthy volunteers. https://clinicaltrials.gov/ct2/show/NCT03605277. Accessed 21 Jan 2021.

  29. ClinicalTrials.gov. A trial to evaluate the pharmacokinetics of ABL001 in healthy and hepatic impaired subjects. https://clinicaltrials.gov/ct2/show/NCT02857868. Accessed 21 Jan 2021.

  30. ClinicalTrials.gov. A study of oral asciminib versus other TKIs in adult patients with newly diagnosed Ph+ CML-CP. https://clinicaltrials.gov/ct2/show/NCT04971226. Accessed 21 Jan 2021.

  31. ClinicalTrials.gov. Asciminib Treatment Optimization in ≥ 3rd Line CML-CP. https://clinicaltrials.gov/ct2/show/NCT04948333. Accessed 21 Jan 2021.

  32. ClinicalTrials.gov. Study of efficacy and safety of CML-CP patients treated with asciminib versus best available therapy, previously treated with 2 or more tyrosine kinase inhibitors. https://clinicaltrials.gov/ct2/show/NCT04795427. Accessed 21 Jan 2021.

  33. ClinicalTrials.gov. Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemia. https://clinicaltrials.gov/ct2/show/NCT04925479. Accessed 21 Jan 2021.

  34. ClinicalTrials.gov. Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation. https://clinicaltrials.gov/ct2/show/NCT04838041. Accessed 8 Apr 2021.

  35. ClinicalTrials.gov. Asciminib Roll-over Study. https://clinicaltrials.gov/ct2/show/NCT04877522. Accessed 7 May 2021.

  36. ClinicalTrials.gov. Managed Access Program (MAP) to Provide Access to Asciminib for Patients With CML in Chronic Phase. https://clinicaltrials.gov/ct2/show/NCT04360005. Accessed 24 Apr 2021.

  37. Shukhov O, Turkina A, Lomaia E, Morozova E, Petrova A, Chitanava T, et al. Asciminib managed-access program (MAP) in Russia. EHA 2022; abstract P718.

  38. Perez-Lamas L, Luna A, Boque C, Giraldo P, Xicoy B, Casado LF, et al. Asciminib in real-life clinical practice, safety and efficacy profile in chronic myeloid leukemia pretreated patients. ASH 2021; abstract 2563.

  39. Innes A, Orovboni V, Claudiani S, Fernando F, Khan A, Byrne J, et al. Asciminib use in CML: the UK experience. EHA 2022; abstract P706.

  40. Kockerols C CB, Janssen JJWM, Billjevens NMA, Klein SK, van Hussen-Daenen LGM, van Gorkom GNY, et al. Clinical outcome of asciminib treatment in a real-world multiresistant CML patient population. EHA 2022; abstract P709.

  41. Breccia M, Russo Rossi AV, Martino B, Abruzzese E, Annunziata M, Binotto G, et al. Asciminib Italian managed access program: efficacy profile in heavily pre-treated CML patients. EHA 2022; abstract P712.

Download references

Acknowledgements

None.

Author information

Authors and Affiliations

  1. Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Via Benevento 6, 00161, Rome, Italy

    Alessandro Laganà, Emilia Scalzulli, Ida Carmosino, Maurizio Martelli & Massimo Breccia

Authors
  1. Alessandro Laganà
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emilia Scalzulli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ida Carmosino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maurizio Martelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Massimo Breccia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Breccia.

Ethics declarations

Conflict of interest

MB received honoraria by Novartis, Pfizer, Incyte, BMS/Celgene, Abbvie. The other authors have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Laganà, A., Scalzulli, E., Carmosino, I. et al. Asciminib as a third line option in chronic myeloid leukemia. Int J Hematol 117, 16–23 (2023). https://doi.org/10.1007/s12185-022-03432-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-022-03432-7

Keywords

Search

Navigation